Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech has demonstrated strong growth in its surgical soft tissue repair products, with a year-over-year increase of 24% in sales, contributing significantly to overall revenue. The company's recent contract with Vizient, the largest group purchasing organization in the U.S., is expected to enhance access to its products and drive future topline growth, alongside improvements in operational efficiency. Furthermore, the continued expansion of its product portfolio and enhancements in its sales and distribution network position Sanara MedTech for sustainable revenue growth and improved profitability in the coming years.

Bears say

Sanara MedTech reported net revenue of $26.3 million, which reflects a 21.5% year-over-year growth, yet this figure fell short of the projected $26.7 million. Key risks influencing a negative outlook include the potential for lower-than-expected revenue growth, challenges in attracting new customers, difficulties in launching new products or services, and risks related to potential dilution. Additionally, the company has seen a reduction in its enterprise value to revenue multiple from 4.3x to 3.0x as telehealth has been removed from its business model, contributing to concerns about its future growth trajectory.

SMTI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Strong Buy based on their latest research and market trends.

According to 1 analysts, SMTI has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.